Disorder of Consciousness — Development of a Point of Care System for Automated Coma Prognosis
Citation(s)
Armanfard N, Komeili M, Reilly JP, Mah R, Connolly JF Automatic and continuous assessment of ERPs for mismatch negativity detection. Annu Int Conf IEEE Eng Med Biol Soc. 2016 Aug;2016:969-972. doi: 10.1109/EMBC.2016.7590863.
Armanfard N, Reilly JP, Komeili M Local Feature Selection for Data Classification. IEEE Trans Pattern Anal Mach Intell. 2016 Jun;38(6):1217-27. doi: 10.1109/TPAMI.2015.2478471. Epub 2015 Sep 14.
Armanfard N, Reilly JP, Komeili M Logistic Localized Modeling of the Sample Space for Feature Selection and Classification. IEEE Trans Neural Netw Learn Syst. 2018 May;29(5):1396-1413. doi: 10.1109/TNNLS.2017.2676101. Epub 2017 Mar 21.
Cao C, Tutwiler RL, Slobounov S Automatic classification of athletes with residual functional deficits following concussion by means of EEG signal using support vector machine. IEEE Trans Neural Syst Rehabil Eng. 2008 Aug;16(4):327-35. doi: 10.1109/TNSRE.2008.918422.
Chiappa KH, Hill RA Evaluation and prognostication in coma. Electroencephalogr Clin Neurophysiol. 1998 Feb;106(2):149-55. doi: 10.1016/s0013-4694(97)00118-1.
Garrido MI, Kilner JM, Stephan KE, Friston KJ The mismatch negativity: a review of underlying mechanisms. Clin Neurophysiol. 2009 Mar;120(3):453-63. doi: 10.1016/j.clinph.2008.11.029. Epub 2009 Jan 31.
Ghosh-Dastidar S, Adeli H, Dadmehr N Principal component analysis-enhanced cosine radial basis function neural network for robust epilepsy and seizure detection. IEEE Trans Biomed Eng. 2008 Feb;55(2 Pt 1):512-8. doi: 10.1109/TBME.2007.905490.
Giacino JT, Fins JJ, Laureys S, Schiff ND Disorders of consciousness after acquired brain injury: the state of the science. Nat Rev Neurol. 2014 Feb;10(2):99-114. doi: 10.1038/nrneurol.2013.279. Epub 2014 Jan 28.
Guldenmund P, Stender J, Heine L, Laureys S Mindsight: diagnostics in disorders of consciousness. Crit Care Res Pract. 2012;2012:624724. doi: 10.1155/2012/624724. Epub 2012 Nov 14.
Guler I, Ubeyli ED Multiclass support vector machines for EEG-signals classification. IEEE Trans Inf Technol Biomed. 2007 Mar;11(2):117-26. doi: 10.1109/titb.2006.879600.
Jennett B, Bond M Assessment of outcome after severe brain damage. Lancet. 1975 Mar 1;1(7905):480-4. doi: 10.1016/s0140-6736(75)92830-5.
Jones C Glasgow coma scale. Am J Nurs. 1979 Sep;79(9):1551-3. No abstract available.
Kane NM, Butler SR, Simpson T Coma outcome prediction using event-related potentials: P(3) and mismatch negativity. Audiol Neurootol. 2000 May-Aug;5(3-4):186-91. doi: 10.1159/000013879.
Khodayari-Rostamabad A, Reilly JP, Hasey GM, de Bruin H, Maccrimmon DJ A machine learning approach using EEG data to predict response to SSRI treatment for major depressive disorder. Clin Neurophysiol. 2013 Oct;124(10):1975-85. doi: 10.1016/j.clinph.2013.04.010. Epub 2013 May 15.
Lew HL, Poole JH, Castaneda A, Salerno RM, Gray M Prognostic value of evoked and event-related potentials in moderate to severe brain injury. J Head Trauma Rehabil. 2006 Jul-Aug;21(4):350-60. doi: 10.1097/00001199-200607000-00006.
Logi F, Fischer C, Murri L, Mauguiere F The prognostic value of evoked responses from primary somatosensory and auditory cortex in comatose patients. Clin Neurophysiol. 2003 Sep;114(9):1615-27. doi: 10.1016/s1388-2457(03)00086-5.
Morlet D, Fischer C MMN and novelty P3 in coma and other altered states of consciousness: a review. Brain Topogr. 2014 Jul;27(4):467-79. doi: 10.1007/s10548-013-0335-5. Epub 2013 Nov 27.
Ravan M, Hasey G, Reilly JP, MacCrimmon D, Khodayari-Rostamabad A A machine learning approach using auditory odd-ball responses to investigate the effect of Clozapine therapy. Clin Neurophysiol. 2015 Apr;126(4):721-30. doi: 10.1016/j.clinph.2014.07.017. Epub 2014 Aug 27.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
